ARCHIVES

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

Early ADT Doesn’t Offer Survival Advantage—ASCO

April 27, 2007

In Brief: NCFA Offers Grants For Research On Impact Of DRGs; ACCC Leaders Dispute HCFA Chief

March 8, 1985

Phase 1 Study Asked to Determine If Drug Administration Timing Improves Results

April 4, 1986

RFA For Patterns Of Care Studies Announced By DCCR

November 10, 1978

DCCP Board Okays Concepts Of New Grants Totaling $1.4 Million Year

February 18, 1983

In Brief: Senate Subcommittee Adds $100 Million For NCI Over House Bill, No Further Action Until Sept.

August 8, 1975